Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) will likely be posting its Q1 2025 quarterly earnings results before the market opens on Thursday, April 24th. Analysts expect Oruka Therapeutics to post earnings of ($0.57) per share for the quarter.
Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last issued its earnings results on Thursday, March 6th. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.19. On average, analysts expect Oruka Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
Oruka Therapeutics Stock Performance
NASDAQ:ORKA traded up $0.08 during mid-day trading on Monday, reaching $9.30. The stock had a trading volume of 309,826 shares, compared to its average volume of 238,394. The business has a 50 day simple moving average of $10.10 and a 200 day simple moving average of $17.15. The firm has a market capitalization of $348.20 million, a price-to-earnings ratio of -1.49 and a beta of 0.47. Oruka Therapeutics has a twelve month low of $5.49 and a twelve month high of $31.13.
Analysts Set New Price Targets
ORKA has been the topic of a number of recent analyst reports. Wedbush reaffirmed an "outperform" rating and set a $40.00 price target on shares of Oruka Therapeutics in a research note on Friday, March 7th. Wolfe Research assumed coverage on shares of Oruka Therapeutics in a report on Tuesday, February 4th. They set an "outperform" rating and a $20.00 price objective on the stock. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $45.00 target price on shares of Oruka Therapeutics in a report on Friday, February 7th. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $39.86.
Read Our Latest Report on ORKA
Insider Buying and Selling at Oruka Therapeutics
In related news, major shareholder Venrock Healthcare Capital Par acquired 88,794 shares of Oruka Therapeutics stock in a transaction dated Friday, February 14th. The shares were acquired at an average cost of $11.44 per share, for a total transaction of $1,015,803.36. Following the completion of the transaction, the insider now directly owns 4,148,428 shares of the company's stock, valued at $47,458,016.32. The trade was a 2.19 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders have acquired 98,339 shares of company stock valued at $1,128,456 over the last quarter. Corporate insiders own 22.67% of the company's stock.
Oruka Therapeutics Company Profile
(
Get Free Report)
Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
See Also
Before you consider Oruka Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oruka Therapeutics wasn't on the list.
While Oruka Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
